---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-031058"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2026-08-04T11:50:16+00:00"
generated_at: "2026-08-04T11:55:18.005929+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics converts $105.8M debt to equity, eliminating all outstanding notes from Chairman Uihlein

## Summary
- Converted $91.0M principal + $14.8M accrued interest ($105.8M total) into 34,376,167 shares at ~$3.07 blended price.
- Post-conversion shares outstanding: 100,849,644; Uihlein owns ~44.3% voting power (49.3% including warrants).
- Sixth $10M credit facility (Dec 2025) remains undrawn and available; no notes issued under it.
- Company must register resale of shares within 180 days per registration rights provisions.
- CEO says conversion 'transformative' for balance sheet, strengthens ability to advance belapectin program.

## SEC filing metadata
- accession: 0001140361-26-031058
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2026-08-04T11:50:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036126031058/0001140361-26-031058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036126031058/ef20079045_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-031058
- JSON: https://secwatch.observer/filing/0001140361-26-031058.json
- Plain text: https://secwatch.observer/filing/0001140361-26-031058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.